dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:43Z | |
dc.date.available | 2018-06-22T09:52:43Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41473 | |
dc.description.abstract | Noncardiogenic pulmonary edema (NCPE) is a rare and less well-recognizable pulmonotoxic syndrome of anticancer therapy than pneumonitis/fibrosis. NCPE is a clinical syndrome characterized by simultaneous presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph, and no evidence of left atrial hypertension/congestive heart failure. The diagnosis of drug-related NCPE relies upon documented exclusion of any infectious, metabolic, or cancer-related causes. The time proximity to therapy with drugs that are known to precipitate NCPE, any preceding episodes of flu-like symptoms during previous chemotherapy courses and possible response to corticosteroids may further support such a diagnosis. Cancer therapeutic agents clearly associated with NCPE are cytarabine, gemcitabine, and interleukin-2, as well as all-trans retinoic acid in acute promyelocytic leukemia patients, while a few other compounds have rarely or occasionally been implicated. The pathophysiology of lung injury in drug-induced NCPE remains unclear. There are indications suggesting that both a direct cytotoxic insult to the lung epithelial cells and induction of a cytokine-triggered inflammatory response may be involved in its pathogenesis. By distinction to drug-induced pulmonary pneumonitis that may lead to permanent pulmonary fibrosis, NCPE if not fatal, can be reversed upon prompt recognition, following immediate discontinuation of the offensive drug and start of intensive supportive treatment and intravenous corticosteroids. | en |
dc.language.iso | eng | en |
dc.source | Oncologist | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Dacarbazine | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Mitomycin | en |
dc.subject | Neoplasms | en |
dc.subject | Vinblastine | en |
dc.subject | Humans | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Granulocyte colony stimulating factor | en |
dc.subject | Pneumonia | en |
dc.subject | Docetaxel | en |
dc.subject | Retinoic acid | en |
dc.subject | Interleukin-2 | en |
dc.subject | Pathogenesis | en |
dc.subject | Clinical feature | en |
dc.subject | Thorax radiography | en |
dc.subject | Drug withdrawal | en |
dc.subject | Corticosteroid | en |
dc.subject | Gemcitabine | en |
dc.subject | Lung edema | en |
dc.subject | Lung toxicity | en |
dc.subject | Noncardiogenic pulmonary edema | en |
dc.subject | Pulmonary edema | en |
dc.subject | Pulmonary toxicity | en |
dc.subject | Acute lung injury | en |
dc.subject | All-trans retinoic acid | en |
dc.subject | Ards | en |
dc.subject | Arsenic trioxide | en |
dc.subject | Arsenic trioxide (as2o3) | en |
dc.subject | Assisted ventilation | en |
dc.subject | Congestive heart failure | en |
dc.subject | Cytarabine | en |
dc.subject | Differential diagnosis | en |
dc.subject | Diuresis | en |
dc.subject | Diuretic agent | en |
dc.subject | Flu like syndrome | en |
dc.subject | Fotemustine | en |
dc.subject | Granulocyte macrophage colony stimulating factor | en |
dc.subject | Hypoxemia | en |
dc.subject | Interleukin 2 | en |
dc.subject | Lung fibrosis | en |
dc.subject | Lung infiltrate | en |
dc.subject | Ncpe | en |
dc.subject | Nitrosourea derivative | en |
dc.subject | Pathophysiology | en |
dc.subject | Recombinant interleukin 2 | en |
dc.subject | Symptomatology | en |
dc.title | Noncardiogenic pulmonary edema: An unusual and serious complication of anticancer therapy | en |
dc.identifier.doi | 10.1634/theoncologist.6-2-153 | |
dc.description.volume | 6 | |
dc.description.issue | 2 | |
dc.description.startingpage | 153 | |
dc.description.endingpage | 161 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |